Nanoparticle technology for treatment of Parkinson’s disease: The role of surface phenomena in reaching the brain

Renal clearance of quantum dots

Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476

Epidemiology of Parkinson's disease

de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110

Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art

Müller, R. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00087-4 · Cited by 3,836

Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles

OWENSIII, D., & PEPPAS, N. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.010 · Cited by 3,637

Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives

Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533

Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles

Cedervall, T., Lynch, I., Lindman, S., Berggård, T., Thulin, E., Nilsson, H., Dawson, K. A., & Linse, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608582104 · Cited by 3,281

Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts

Lundqvist, M., Stigler, J., Elia, G., Lynch, I., Cedervall, T., & Dawson, K. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805135105 · Cited by 3,109

Nanoparticle PEGylation for Imaging and Therapy

Jokerst, J. V., Lobovkina, T., Zare, R. N., & Gambhir, S. S. (2011) · Nanomedicine · doi:10.2217/nnm.11.19 · Cited by 2,113

Physical−Chemical Aspects of Protein Corona: Relevance to in Vitro and in Vivo Biological Impacts of Nanoparticles

Monopoli, M. P., Walczyk, D., Campbell, A., Elia, G., Lynch, I., Baldelli Bombelli, F., & Dawson, K. A. (2011) · Journal of the American Chemical Society · doi:10.1021/ja107583h · Cited by 1,835

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment

Chaudhuri, К. R., & Schapira, A. H. V. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70068-7 · Cited by 1,818

Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases

Chin-Chan, M., Navarro-Yepes, J., & Quintanilla‐Vega, B. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00124 · Cited by 746

Non-Ionic Surfactants for Stabilization of Polymeric Nanoparticles for Biomedical Uses

Cortés, H., Hernández‐Parra, H., Bernal-Chávez, S. A., Prado-Audelo, M. L. D., Caballero-Florán, I. H., Borbolla‐Jiménez, F. V., González‐Torres, M., Magaña, J. J., & Leyva‐Gómez, G. (2021) · Materials · doi:10.3390/ma14123197 · Cited by 324

Stimuli-responsive In situ gelling system for nose-to-brain drug delivery

Agrawal, M., Saraf, S., Saraf, S., Dubey, S. K., Puri, A., Gupta, U. D., Kesharwani, P., Ravichandiran, V., Kumar, P., Naidu, V. G. M., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.044 · Cited by 304

Nano carriers for drug transport across the blood–brain barrier

Li, X., Tsibouklis, J., Weng, T., Zhang, B., Yin, G., Feng, G., Cui, Y., Savina, I. N., Mikhalovska, L. I., Sandeman, S. R., et al. (2016) · Journal of drug targeting · doi:10.1080/1061186x.2016.1184272 · Cited by 289

The protein corona and its effects on nanoparticle-based drug delivery systems

Li, H., Wang, Y., Tang, Q., Yin, D., Tang, C., He, E., Zou, L., & Peng, Q. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.019 · Cited by 265

Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment

Bi, C., Wang, A., Chu, Y., Liu, S., Mu, H., Liu, W., Wu, Z., Sun, K., & Li, Y. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s120939 · Cited by 203

Nanocarriers for targeted drug delivery

Shah, A., Aftab, S., Nisar, J., Ashiq, M. N., & Iftikhar, F. J. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102426 · Cited by 161

Poly(trehalose) Nanoparticles Prevent Amyloid Aggregation and Suppress Polyglutamine Aggregation in a Huntington’s Disease Model Mouse

Debnath, K., Pradhan, N., Singh, B. K., Jana, N. R., & Jana, N. R. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b06510 · Cited by 149

Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders

Md, S., Bhattamisra, S. K., Zeeshan, F., Shahzad, N., Mujtaba, M. A., Meka, V. S., Radhakrishnan, A. K., Kesharwani, P., Baboota, S., & Ali, J. (2017) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2017.09.022 · Cited by 140

Neurotheranostics as Personalized Medicines

Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124

PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases

Cunha, A., Gaubert, A., Latxague, L., & Dehay, B. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071042 · Cited by 129

Multi-Target Mechanisms of Phytochemicals in Alzheimer’s Disease: Effects on Oxidative Stress, Neuroinflammation and Protein Aggregation

Sharifi-Rad, J., Rapposelli, S., Sestito, S., Herrera-Bravo, J., Arancibia-Diaz, A., Salazar, L. A., Yeskaliyeva, B., Beyatli, A., Leyva-Gómez, G., González-Contreras, C., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091515 · Cited by 125

Neuroprotective Effects of Curcumin in Neurodegenerative Diseases

Genchi, G., Lauria, G., Catalano, A. A., Carocci, A., & Sinicropi, M. S. (2024) · Foods · doi:10.3390/foods13111774 · Cited by 129

A Reevaluation of Chitosan-Decorated Nanoparticles to Cross the Blood-Brain Barrier

Cortés, H., Alcalá-Alcalá, S., Caballero-Florán, I. H., Bernal-Chávez, S. A., Ávalos‐Fuentes, A., González‐Torres, M., Carmen, M. G., Figueroa‐González, G., Reyes‐Hernández, O. D., Florán, B., et al. (2020) · Membranes · doi:10.3390/membranes10090212 · Cited by 108

Insights into Terminal Sterilization Processes of Nanoparticles for Biomedical Applications

Bernal-Chávez, S. A., Prado-Audelo, M. L. D., Caballero-Florán, I. H., Giraldo‐Gómez, D. M., Figueroa‐González, G., Reyes‐Hernández, O. D., Carmen, M. G., González‐Torres, M., Cortés, H., & Leyva‐Gómez, G. (2021) · Molecules · doi:10.3390/molecules26072068 · Cited by 92

In vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery

Arısoy, S., SAYINER, Ö., Çomoğlu, T., Önal, D., Atalay, Ö., & Pehli̇vanoğlu, B. (2020) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2020.1740257 · Cited by 89

Chemically exfoliated WS2 nanosheets efficiently inhibit amyloid β-peptide aggregation and can be used for photothermal treatment of Alzheimer’s disease

Li, M. C., Zhao, A., Dong, K., Li, W., Ren, J., & Qu, X. (2015) · Nano Research · doi:10.1007/s12274-015-0821-z · Cited by 91

Functional single-walled carbon nanotubes ‘CAR’ for targeting dopamine delivery into the brain of parkinsonian mice

Guo, Q., You, H., Yang, X., Lin, B., Zhu, Z., Lu, Z., Li, X., Zhao, Y. S., Mao, L., Shen, S., et al. (2017) · Nanoscale · doi:10.1039/c7nr02682j · Cited by 70

Fullerenes: Historical background, novel biological activities versus possible health risks

Pesado-Gómez, C., Serrano‐García, J. S., Amaya‐Flórez, A., Pesado-Gómez, G., Soto‐Contreras, A., Morales‐Morales, D., & Colorado‐Peralta, R. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215550 · Cited by 61

The blood–brain barrier and beyond: Nano-based neuropharmacology and the role of extracellular matrix

Henrich‐Noack, P., Nikitovic, D., Neagu, M. T., Docea, A. O., Engin, A. B., Gelperina, S. E., Штильман, М. И., Mitsias, P. D., Tzanakakis, G. N., Gozes, I., et al. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.01.016 · Cited by 58

Nanomaterials for Parkinson disease: Recent progress

Ghazy, E., Rahdar, A., Barani, M., & Kyzas, G. Z. (2020) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2020.129698 · Cited by 56

Brain aging and Parkinson’s disease: New therapeutic approaches using drug delivery systems

Rodríguez‐Nogales, C., Garbayo, E., Carmona‐Abellán, M., Luquín, M. R., & Blanco‐Prieto, M. J. (2015) · Maturitas · doi:10.1016/j.maturitas.2015.11.009 · Cited by 54

Rapid and efficient crossing blood-brain barrier: Hydrophobic drug delivery system based on propionylated amylose helix nanoclusters

Gao, W., Liu, Y., Jing, G.-X., Li, K., Zhao, Y., Sha, B., Wang, Q., & Wu, D. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.10.045 · Cited by 54

Biodegradable Nanoparticles Loaded with Levodopa and Curcumin for Treatment of Parkinson’s Disease

Mogharbel, B. F., Cardoso, M. A., Irioda, A. C., Stricker, P. E. F., Slompo, R. C., Appel, J. M., de Oliveira, N. B., Perussolo, M. C., Saçaki, C. S., da Rosa, N. N., et al. (2022) · Molecules · doi:10.3390/molecules27092811 · Cited by 52

Triple Drug Combination of Zidovudine, Efavirenz and Lamivudine Loaded Lactoferrin Nanoparticles: an Effective Nano First-Line Regimen for HIV Therapy

Kumar, P., Lakshmi, Y. S., & Kondapi, A. K. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-2048-4 · Cited by 52

Emerging well-tailored nanoparticulate delivery system based on in situ regulation of the protein corona

Li, Z., Wang, Y., Zhu, J., Zhang, Y., Zhang, W., Zhou, M., Luo, C., Li, Z. J., Cai, B., Gui, S., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.007 · Cited by 50

Alzheimer’s Disease and Parkinson’s Disease: A Review of Current Treatment Adopting a Nanotechnology Approach

Trompetero, A., Gordillo, A., del Pilar, M. C., Cristina, V., & Bustos, R. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612823666170828133059 · Cited by 49

Emerging Nanotechnology for Treatment of Alzheimer’s and Parkinson’s Disease

Li, A., Tyson, J., Patel, S. G., Patel, M., Katakam, S., Mao, X., & He, W. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.672594 · Cited by 48

Nanomedicine and drug delivery: A comprehensive review of applications and challenges

Singh, K., Singhal, S., Pahwa, S., Sethi, V. A., Sharma, S., Singh, P., Kale, R. D., Ali, S. W., & Sagadevan, S. (2024) · Nano-Structures & Nano-Objects · doi:10.1016/j.nanoso.2024.101403 · Cited by 50

Targeted therapy of breast tumor by PLGA-based nanostructures: The versatile function in doxorubicin delivery

Dongsar, T. S., Dongsar, T. T., Molugulu, N., Annadurai, S., Wahab, S., Gupta, N., & Kesharwani, P. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116455 · Cited by 46

Alginate/magnetite hybrid beads for magnetically stimulated release of dopamine

Kondaveeti, S., Cornejo, D. R., & Petri, D. F. S. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.11.058 · Cited by 45

Twenty-Five Years of Nano-Bio-Materials: Have We Revolutionized Healthcare?

Pandit, A. S., & Zeugolis, D. I. (2016) · Nanomedicine · doi:10.2217/nnm.16.42 · Cited by 45

Lipid-based nanodelivery approaches for dopamine-replacement therapies in Parkinson's disease: From preclinical to translational studies

Karthivashan, G., Ganesan, P., Park, S., Lee, H., & Choi, D. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119704 · Cited by 47

Nanoneuromedicine for management of neurodegenerative disorder

Dwivedi, N., Shah, J., Mishra, V. K., Tambuwala, M. M., & Kesharwani, P. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.12.021 · Cited by 44

Leveraging the interplay of nanotechnology and neuroscience: Designing new avenues for treating central nervous system disorders

Smith, E. S., Porterfield, J. E., & Kannan, R. M. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.02.009 · Cited by 45

Tumor cellular membrane camouflaged liposomes as a non-invasive vehicle for genes: specific targeting toward homologous gliomas and traversing the blood–brain barrier

Zhao, Y., Shen, B., Li, X.-Z., Tong, M., Xue, P., Chen, R., Yao, Q., Chen, B., Xiao, J., & Xu, H. (2020) · Nanoscale · doi:10.1039/d0nr04212a · Cited by 37

Emerging Promise of Nanoparticle-Based Treatment for Parkinson’s disease

(2020) · Biointerface Research in Applied Chemistry · doi:10.33263/briac106.71357151 · Cited by 37

Box-Behnken Design-Based Optimization and Evaluation of Lipid-Based Nano Drug Delivery System for Brain Targeting of Bromocriptine

Spandana, K. M. A., Angolkar, M., Rahamathulla, M., Thajudeen, K. Y., Ahmed, M. M., Farhana, S. A., Shivanandappa, T. B., Paramshetti, S., Osmani, R. A. M., & Natarajan, J. (2024) · Pharmaceuticals · doi:10.3390/ph17060720 · Cited by 36

Neuroprotective Potential and Chemical Profile of Alternatively Cultivated Ganoderma lucidum Basidiocarps

Ćilerdžić, J. L., Sofrenić, I. V., Tešević, V., Brčeski, I., Duletić-Laušević, S. N., Vukojević, J. B., & Stajić, M. M. (2018) · Chemistry & Biodiversity · doi:10.1002/cbdv.201800036 · Cited by 35

Delivery systems for theranostics in neurodegenerative diseases

Li, Y., Liu, R., Ji, W., Li, Y., Liu, L., & Zhang, X. (2018) · Nano Research · doi:10.1007/s12274-018-2067-z · Cited by 35

Recent Advances in Nanomaterials for Asthma Treatment

Xu, Z., Guo, X., Gu, Y., Zheng, H., Zhou, Z., Wang, X., Jiang, S., Wang, G., Xu, C., & Wang, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214427 · Cited by 32

In situ apolipoprotein E-enriched corona guides dihydroartemisinin-decorating nanoparticles towards LDLr-mediated tumor-homing chemotherapy

Li, Z., Zhu, J., Wang, Y., Zhou, M. L., Li, D., Zheng, S., Yin, L., Luo, C., Zhang, H., Zhong, L., et al. (2019) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2019.05.002 · Cited by 31

Development of immunotherapy and nanoparticles-based strategies for the treatment of Parkinson’s disease

Duwa, R., Jeong, J., & Yook, S. (2021) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-021-00521-3 · Cited by 31

Repositioning of drugs for Parkinson’s disease and pharmaceutical nanotechnology tools for their optimization

Hernández‐Parra, H., Cortés, H., Ávalos‐Fuentes, J. A., Prado-Audelo, M. L. D., Florán, B., Leyva‐Gómez, G., Sharifi‐Rad, J., & Cho, W. C. S. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01612-5 · Cited by 30

Dopamine-loaded Poly (butyl cyanoacrylate) Nanoparticles Reverse Behavioral Deficits in Parkinson’s Animal Models

Jahansooz, F., Ebrahimi-Hosseinzadeh, B., Hatamian-Zarmi, A., Hadi, F., Hojjati, S. M. M., & Shahpasand, K. (2020) · Therapeutic Delivery · doi:10.4155/tde-2020-0026 · Cited by 27

Neuroprotective effects of L-Dopa-modified zinc oxide nanoparticles on the rat model of 6-OHDA-ınduced Parkinson’s disease

Yeni, Y., Genç, S., Ertuğrul, M. S., Nadaroğlu, H., Gezer, A., Mendĭl, A. S., & Hacımüftüoğlu, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-69324-4 · Cited by 26

REMOVED: Mild traumatic brain injury exacerbates Parkinson's disease induced hemeoxygenase-2 expression and brain pathology: Neuroprotective effects of co-administration of TiO2 nanowired mesenchymal stem cells and cerebrolysin

Sharma, A., Muresanu, D. F., Nozari, A., Lafuente, J. V., Sahib, S., Tian, Z. R., Buzoianu, A. D., Patnaik, R., Wiklund, L., & Sharma, H. S. (2020) · Progress in brain research · doi:10.1016/bs.pbr.2020.09.010 · Cited by 23

Development and application of nano-flavor-drug carriers in neurodegenerative diseases

Ji, W., Xiao, Z.-B., Liu, G., & Zhang, X. (2017) · Chinese Chemical Letters · doi:10.1016/j.cclet.2017.06.024 · Cited by 22

Studying CNS effects of Traditional Chinese Medicine using zebrafish models

Wang, D., Hu, G., Wang, J., Yan, D., Wang, M., Yang, L., Serikuly, N., Alpyshov, E. T., Demin, K. A., Galstyan, D. S., et al. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113383 · Cited by 22

Designing nanoformulation for the nose‐to‐brain delivery in Parkinson's disease: Advancements and barrier

Kiran, P., Debnath, S. K., Neekhra, S., Pawar, V. S., Khan, A., Dias, F., Pallod, S., & Srivastava, R. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1768 · Cited by 26

Evolution of anti-parkinsonian activity of monoterpenoid (1 R ,2 R ,6 S )-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in various in vivo models

Вальдман, Е. А., Капица, И. Г., Иванова, Е. А., Voronina, T., Ardashov, O. V., Volcho, K. P., Хазанов, В. А., & Salakhutdinov, N. F. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.09.022 · Cited by 18

Nanomedicine against Alzheimer’s and Parkinson’s Disease

Tandon, A., Singh, S. J., & Chaturvedi, R. K. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201021140904 · Cited by 20

Mathematical Optimisation of Magnetic Nanoparticle Diffusion in the Brain White Matter

Tian, Y., Yang, Y., Zhan, W., & Dini, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032534 · Cited by 18

Dual‐Functionalization Device for Therapy through Dopamine Release and Monitoring

Fabregat, G., Giménez, A., Díaz, A., Puiggalı́, J., & Alemán, C. (2018) · Macromolecular Bioscience · doi:10.1002/mabi.201800014 · Cited by 18

Evaluation of anti-cancer properties of pegylated ethosomal paclitaxel on human melanoma cell line SKMEL- 3

Eskolaky, E., Ardjmand, M., & Akbarzadeh, A. (2015) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v14i8.14 · Cited by 16

Deciphering the Role of Nanoparticle-based Treatment for Parkinson’s Disease

Moni, M. M. R., Begum, M. M., Uddin, M. S., & Ashraf, G. M. (2021) · Current Drug Metabolism · doi:10.2174/1389200222666210202110129 · Cited by 15

Dual-targeting tigecycline nanoparticles for treating intracranial infections caused by multidrug-resistant Acinetobacter baumannii

Lan, X., Qin, S., Liu, H., Guo, M., Zhang, Y., Jin, X., Duan, X., Sun, M., Liu, Z., Wang, W., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02373-z · Cited by 15

Biodegradable polymeric nanostructures: design and advances in oral drug delivery for neurodegenerative disorders

Ribeiro, A. M., Veiga, F., & Figueiras, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-47720-8.00003-1 · Cited by 15

Perspectives of nanobiotechnology and biomacromolecules in parkinson’s disease

Adam, H., Gopinath, S. C. B., Arshad, M. K. M., Adam, T., & Hashim, U. (2019) · Process Biochemistry · doi:10.1016/j.procbio.2019.07.019 · Cited by 16

Recent Advancements in Nanomaterials: A Promising Way to Manage Neurodegenerative Disorders

Nguyen, T. T., Nguyen‐Thi, P., Nguyen, T. H. A., Ho, T.-T., An, T. N. M., Toi, V. V., & Giau, V. V. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00654-1 · Cited by 14

Advances in Alzheimer’s disease therapeutics: biochemistry, exploring bioactive compounds and novel approaches

Atoki, A. V., Aja, P. M., Ondari, E. N., & Shinkafi, T. S. (2023) · International Journal of Food Properties · doi:10.1080/10942912.2023.2243050 · Cited by 20

PLGA nanomedical consignation: A novel approach for the management of prostate cancer

Dongsar, T. S., Dongsar, T. T., Gupta, G., Alsayari, A., Wahab, S., & Kesharwani, P. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.123808 · Cited by 14

New Perspectives of Gene Therapy on Polyglutamine Spinocerebellar Ataxias: From Molecular Targets to Novel Nanovectors

Borbolla‐Jiménez, F. V., Prado-Audelo, M. L. D., Cisneros, B., Caballero-Florán, I. H., Leyva‐Gómez, G., & Magaña, J. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071018 · Cited by 13

Nanoparticles With Affinity for α-Synuclein Sequester α-Synuclein to Form Toxic Aggregates in Neurons With Endolysosomal Impairment

Jiang, P., Gan, M., Yen, S.-H. C., & Dickson, D. W. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.738535 · Cited by 13

Advancements in nose-to-brain drug targeting for Alzheimer’s disease: a review of nanocarriers and clinical insights

Komal, K., Ghosh, R., Sil, D., Sharma, R., Kumar, S., Pandey, P., & Kumar, M. (2025) · Inflammopharmacology · doi:10.1007/s10787-024-01636-3 · Cited by 15

Inorganic Nanoparticles and Their Strategies to Enhance Brain Drug Delivery

Toledo, E. G., Velasco-Aguirre, C., & Kogan, M. J. (2020) · Neuromethods · doi:10.1007/978-1-0716-0838-8_6 · Cited by 12

Progress, Opportunities, and Challenges of Magneto-Plasmonic Nanoparticles under Remote Magnetic and Light Stimulation for Brain-Tissue and Cellular Regeneration

Yuan, M., Harnett, M. C., Yan, T., Georgas, E., Qin, Y., Zhou, H.-C. “., & Wang, Y. (2022) · Nanomaterials · doi:10.3390/nano12132242 · Cited by 13

Nanotechnology in Parkinson’s Disease: overcoming drug delivery challenges and enhancing therapeutic outcomes

Ali, I., Adil, M., Imran, M., Qureshi, S. A., Qureshi, S., Hasan, N., & Ahmad, F. J. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01799-8 · Cited by 11

Advanced strategies for enhancing the neuroprotective potential of curcumin: delivery systems and mechanistic insights in neurodegenerative disorders

Panda, P., Mohanty, S., Gouda, S. R., Baral, T. C., Mohanty, A., Nayak, J., & Mohapatra, R. (2025) · Nutritional Neuroscience · doi:10.1080/1028415x.2025.2472773 · Cited by 12

Nanotechnology-based Targeting of Neurodegenerative Disorders: A Promising Tool for Efficient Delivery of Neuromedicines

Rajpoot, K. (2020) · Current Drug Targets · doi:10.2174/1389450121666200106105633 · Cited by 12

Curcumin for parkinson´s disease: potential therapeutic effects, molecular mechanisms, and nanoformulations to enhance its efficacy

Cortés, H., Reyes‐Hernández, O. D., González‐Torres, M., Vizcaíno‐Dorado, P. A., Prado-Audelo, M. L. D., Alcalá-Alcalá, S., Sharifi‐Rad, J., Figueroa‐González, G., Carmen, M. G., Florán, B., et al. (2021) · Cellular and Molecular Biology · doi:10.14715/cmb/2021.67.1.15 · Cited by 10

Evaluation of the Transport and Binding of Dopamine-Loaded PLGA Nanoparticles for the Treatment of Parkinson’s Disease Using In Vitro Model Systems

Danz, K., Fleddermann, J., Koch, M., Fecioru, E., Maahs, L., Kinsinger, N., Krämer, J., Kraegeloh, A., & Wagner, S. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16050571 · Cited by 9

Effect of pramipexole alginate nanodispersion (PAND) on the transgenic Drosophila expressing human alpha synuclein in the brain

Siddique, Y. H., Naz, F., Khan, W., Jyoti, S., Singh, B. R., & Naqvi, A. H. (2017) · Journal of Applied Biomedicine · doi:10.1016/j.jab.2017.11.002 · Cited by 9

Nanotechnology-based Drug Delivery for Alzheimer's and Parkinson's Diseases

Nguyen‐Thi, P., Ho, T.-T., Nguyen, T. T., & Vo, G. V. (2023) · Current Drug Delivery · doi:10.2174/1567201820666230707113405 · Cited by 8

Nano-Osmolyte Conjugation: Tailoring the Osmolyte-Protein Interactions at the Nanoscale

Sharma, H., Dar, T. A., Wijayasinghe, Y. S., Sahoo, D., & Poddar, N. K. (2023) · ACS Omega · doi:10.1021/acsomega.3c07248 · Cited by 8

Orally Administered Nanotherapeutics For Parkinson’s Disease: An Old Delivery System Yet More Acceptable

Aggarwal, N., Qamar, Z., Rehman, S., Baboota, S., & Ali, J. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200406072451 · Cited by 7

From the nose to the brain, nanomedicine drug delivery

Zeeshan, F., Mishra, D. K., & Kesharwani, P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820466-5.00008-9 · Cited by 7

Anti-Parkinson potential of hesperetin nanoparticles: in vivo and in silico investigations

Pasala, P. K., Prasanth, D., Rudrapal, M., Challa, R. R., Ahmad, S. F., Vallamkonda, B., & Ram Babu, R. (2024) · Natural Product Research · doi:10.1080/14786419.2024.2344740 · Cited by 6

Nanopartículas poliméricas de administración intranasal para la liberación de activos en el sistema nervioso central

García-Corvillo, M. D. P. (2016) · Ars Pharmaceutica (Internet) · doi:10.30827/ars.v57i1.4384 · Cited by 6

Nitroxide-containing amphiphilic polymers prepared by simplified electrochemically mediated ATRP as candidates for therapeutic antioxidants

Zaborniak, I., Pieńkowska, N., Chmielarz, P., Bartosz, G., Dziedzic, A., & Sadowska‐Bartosz, I. (2023) · Polymer · doi:10.1016/j.polymer.2023.125885 · Cited by 5

Nanotechnology and Parkinson’s disease

Mavridis, I. N., Meliou, M., Pyrgelis, E.-S., & Agapiou, E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813667-6.00001-2 · Cited by 5

Curcumin-Loaded Nanoparticles in Neurodegenerative Diseases: Alzheimer’s, Parkinson’s, and Amyotrophic Lateral Sclerosis

PALANISAMY, S., Balasubramanian, A., Kanchana, M., Sisubalan, N., & Selvakesavan, R. K. (2025) · Nanotechnology in the life sciences · doi:10.1007/978-3-031-80185-3_8 · Cited by 5

Nanopharmaceuticals

Quintanar‐Guerrero, D., Leyva‐Gómez, G., Magaña-Vergara, N. E., & Mendoza‐Muñoz, N. (2022) · Wiley eBooks · doi:10.1002/9781119558026.ch4 · Cited by 5

Emerging anti-inflammatory nanosystems targeted to the brain

Mahanta, A. K., Gothwal, A., Chaulagain, B., Muolokwu, C. E., Tagoe, B., Lamsal, B., Belin, M. A. F., & Singh, J. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2552103 · Cited by 4

Emerging Nanotechnology for the Treatment and Diagnosis of Parkinson’s Disease (PD) and Alzheimer’s Disease (AD)

Kotha, S., Sriparna, M., Tyson, J., Li, A., He, W., & Mao, X. (2024) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-031-49744-5_5 · Cited by 4

Advances and challenges toward neural regenerative medicine

Dehghani, P., Jahed, V., & Zarrabi, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820223-4.00001-2 · Cited by 4

Therapeutic Implications of Nanopharmaceuticals in Skin Delivery

Mota, A. H., Santos-Rebelo, A., Almeida, A. J., & Reis, C. P. (2020) · Environmental chemistry for a sustainable world · doi:10.1007/978-3-030-44925-4_6 · Cited by 4

Current treads of targeted nanoparticulate carriers for the treatment of Alzheimer’s disease

Gheidari, D., & Bayat, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85544-0.00005-8 · Cited by 3

Recent Advances in Nanocarrier-Based Brain-Targeted Drug Delivery for Effective Treatment of Central Nervous System Disorders

Sarwal, A., Singh, G., Prasad, P., Sharma, S., & Ali, W. (2020) · Springer eBooks · doi:10.1007/978-3-030-41858-8_9 · Cited by 2

Application of nano- and micro-particle-based approaches for selected bronchodilators in management of asthma

Singh, S., Aparna, Sharma, N., Gupta, J., Kyada, A., Nathiya, D., Behl, T., Gupta, S., Anwer, M. K., Gulati, M., et al. (2024) · 3 Biotech · doi:10.1007/s13205-024-04051-1 · Cited by 1

Gene therapy in neurodegenerative disorders

Ali, H. T., Sula, I., Elrefaey, A., Ashour, Y., Eltaras, M. M., Mohamed, H., & Meshref, M. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15702-8.00036-1 · Cited by 1

Expanding the Arsenal of Nanocarriers Against Parkinson Disease: Success so Far Roads Ahead

Devi, N., Dhiman, S., Dora, C. P., Singh, T. G., & Awasthi, A. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03234-0 · Cited by 1

Brain-targeting lipid nanoparticles of nicotinamide mononucleotide: preparation, optimization, and characterization

Lin, Y., Zhao, F., Wang, J., Ping, S., Wu, K., Chen, Y., Zheng, X., & Xu, H. (2026) · Frontiers in Chemistry · doi:10.3389/fchem.2026.1759167 · Cited by 1

Polymeric-Based Theranostic Nanocarriers of Neuroprotective Drugs: Development, Imaging, and Bioanalysis

Szczepanowicz, K., Procner, M., Szczęch, M., Łopuszyńska, N., Jantas, D., Regulska, M., Leśkiewicz, M., Jasiński, K., Stachurski, K., Szyk‐Warszyńska, L., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00170 · Cited by 1

Nanoparticular Drug Delivery Systems in the Treatment Central Nervous System Diseases: Review

Arısoy, S., SAYINER, Ö., & Çomoğlu, T. (2017) · Turkiye Klinikleri Journal of Pharmacy Sciences · doi:10.5336/pharmsci.2017-56331

Nasal delivery nanoparticles

Obulesu, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819882-7.00008-8

Insights into Sub-20 nm Nanocarriers (3-helix Micelles) at the Molecular and Cellular Level

Jung, B. T. (2020) · eScholarship (California Digital Library)

Additional file 1 of Dual-targeting tigecycline nanoparticles for treating intracranial infections caused by multidrug-resistant Acinetobacter baumannii

Lan, X., Qin, S., Liu, H., Guo, M., Zhang, Y., Jin, X., Duan, X., Sun, M., Liu, Z., Wang, W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26699807

Integrative Nanomedicine Approaches and Secondary Metabolites in Neurodegenerative Diseases

Çakar, B., Çadirci, C., & Kilic, K. D. (2026) · IGI Global eBooks · doi:10.4018/979-8-3373-1365-8.ch013

Nanoparticles for drug delivery in Parkinson’s disease

Baskin, J., Jeon, J. E., & Lewis, S. J. G. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10291-x · Cited by 67

Recent Advancement in the Nanoparticles Mediated Therapeutics of Parkinson’s Disease

Chaturvedi, V. K., Singh, P., & singh, M. (2021) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781681087726121010014 · Cited by 8

Theoretical and applied concepts of nanocarriers for the treatment of Parkinson's diseases

Bhosale, A., Paul, G., Mazahir, F., & Yadav, A. K. (2022) · OpenNano · doi:10.1016/j.onano.2022.100111 · Cited by 15

Nanomedicine to Overcome Current Parkinson’s Treatment Liabilities: A Systematic Review

Hawthorne, G. H., Bernuci, M. P., Bortolanza, M., Tumas, V., Issy, A. C., & Bel, E. A. D. (2016) · Neurotoxicity Research · doi:10.1007/s12640-016-9663-z · Cited by 24

Deciphering the Role of Nanoparticle-based Treatment for Parkinson’s Disease

Moni, M. M. R., Begum, M. M., Uddin, M. S., & Ashraf, G. M. (2021) · Current Drug Metabolism · doi:10.2174/1389200222666210202110129 · Cited by 15